Navigation Links
Promising Malaria Vaccine May Save Children's Lives
Date:10/18/2011

By Amanda Gardner
HealthDay Reporter

TUESDAY, Oct. 18 (HealthDay News) -- In an important first, a new vaccine has been shown to cut the risk of malaria in young African children by about half, according to research announced Tuesday.

Although the effectiveness shown in this Phase 3 trial is far less than the near-100 percent effectiveness often seen in childhood vaccines for other illnesses in the West, the findings are promising, given that malaria kills some 800,000 people in sub-Saharan Africa alone each year.

"This potentially translates into [the prevention of] tens of millions of cases of malaria in children," said Dr. Tsiri Agbenyega, a principal investigator of the trial.

Other experts agreed.

"This is really important because it's a viable strategy against a major killer of children in the world," added Dr. Kenneth Bromberg, chairman of pediatrics and director of the Vaccine Research Center at the Brooklyn Hospital Center, New York City.

This is also the first vaccine that is successful against a parasite, in this case Plasmodium falciparum, which causes mosquito-transmitted malaria.

The results -- the first from the Phase 3 trial -- were announced Tuesday at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, and published simultaneously online in the New England Journal of Medicine.

The trial was funded by GlaxoSmithKline (GSK) Biologicals and the PATH Malaria Vaccine Initiative, which are developing the vaccine together with African research centers.

Speaking at a news briefing Tuesday, Andrew Witty, CEO of GSK, said he is "hopeful we're going to be able to bring the vaccine to children in Africa perhaps as early as 2015."

The trial enrolled more than 15,400 children from seven countries in sub-Saharan Africa in two age groups: 6-12 weeks old and 5 to 17 months.

Children were assigned to one of two groups, o
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
2. First blinded study of venous insufficiency prevalence in MS shows promising results
3. Promising therapy for relapsing multibple sclerosis
4. New strategy produces promising advance in cancer vaccines
5. Sytropin HGH Shows Promising Anti-Aging Results
6. Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
7. New smoking cessation therapy proves promising
8. SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients
9. Promising strategy for treatment of lung cancer
10. McMaster researcher leads development of promising drug for inflammation
11. Promising hormone may help reduce malnutrition in gastric cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Promising Malaria Vaccine May Save Children's Lives
(Date:9/1/2014)... (PRWEB) September 02, 2014 “Australia Hernia ... on the Australia Hernia Repair market. The report provides ... and average prices (in US dollars) within market segments ... and Synthetic 3D Meshes) ,     Composite Meshes and ... a surgical operation for the correction of a hernia ...
(Date:9/1/2014)... Sept. 1, 2014 (HealthDay News) -- Having regular family ... health effects of "cyberbullying," a new study suggests. ... thoughts, according to experts. "One in five adolescents ... for Health and Social Policy at McGill University in ... adolescents use social media, and online harassment and abuse ...
(Date:9/1/2014)... health and substance use problems in adolescents but ... consequences of cyberbullying and also be beneficial for ... Ph.D., of McGill University, Montreal, Canada, and colleagues. ... experienced recent online bullying and cyberbullying, like traditional ... problems in teens as well as the misuse ...
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. 30, ... experimental drug was more effective than standard treatment at ... According to the study authors, the trial was stopped ... drug, dubbed LCZ696. In the trial, 26.5 ... either died or were hospitalized due to heart failure, ...
(Date:9/1/2014)... News) -- Watching action shows on TV may be bad ... much more snack food while watching action films and programs ... "We find that if you,re watching an action movie ... author Aner Tal, of the Cornell Food and Brand Lab, ... more distracting the program is, the more you will eat." ...
Breaking Medicine News(10 mins):Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 2Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 3Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 4Health News:Family Meals May Defuse Cyberbullying's Impact, Study Says 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 3Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2
... halt premature labor may be associated with brain damage and intestinal ... on the issue published today in American Journal of Obstetrics and ... are faced with the possibility of delivering a baby who is ... will be given both a tocolytic agent, or drug used to ...
... (positron emission tomography) that measures uptake of sugar in ... type of dementia often mistaken for Alzheimers disease, a ... has found. , The scan, FDG-PET, helped six doctors ... dementia (FTD) and Alzheimers in almost 90 percent of ...
... year of advancing cancer research, the American Association for ... Europe, and Asia. The AACR has teamed with ... Science, Technology and Research (A*STAR) to hold the first ... Singapore: the AACR Centennial Conference on Translational Cancer Medicine: ...
... 1, 2007) Diabetes is a very common illness that ... it is estimated an additional 54 million Americans have pre-diabetes, ... are higher than normal but not high enough for a ... determine whether glucose and insulin levels are associated with a ...
... ADA President Mark J. Feldman:, "The American Dental ... for introducing legislation that will help bring more,dentists into ... too many people lack sufficient access to the basic ... Native American Full Access to Dental Care Act (H.R. ...
... Wash., Nov. 1 BLU-MED Response Systems ... and distribution,facility near Boise, Idaho. BLU-MED produces ... use as mobile field hospitals,emergency medical stations, ... facilities are used by Federal, state and ...
Cached Medicine News:Health News:Common drug for stopping preterm labor may be harmful for babies 2Health News:PET scan distinguishes Alzheimer's from other dementia 2Health News:PET scan distinguishes Alzheimer's from other dementia 3Health News:Emerging therapies with a focus on Asian populations mark the AACR Centennial Conference 2Health News:Increased glucose level is a strong risk factor for colorectal cancer 2Health News:Increased glucose level is a strong risk factor for colorectal cancer 3Health News:Statement by ADA President Mark J. Feldman on the Native American Full Access to Dental Care Act 2Health News:BLU-MED Response Systems Announces New Production Facility in Idaho 2
(Date:9/1/2014)... 2014 Reportbuyer.com has added a new ... Lasers and Energy Devices Market Outlook to 2020, ... Brazil Aesthetic Lasers and Energy Devices Market ... GlobalData,s new report, "Brazil Aesthetic Lasers and ... market data on the Brazil Aesthetic Lasers and ...
(Date:9/1/2014)... NEW YORK , Sept. 1, 2014 /PRNewswire/ ... new market research report is available in its ... Edition), 2014 - 2024 ... conjugates (ADCs) are a new class of therapeutic ... small pharmaceutical companies. Generally addressed as the marriage ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue:  Drug Discovery Technologies - A Global ... The development of new drugs ... extensive expenditure, in addition to consuming a lot ... new drug involves the utilizing high-throughput screening of ...
Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11
... Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite,BioPharma (TASE:CFBI), a ... Exchange, proceeds with the development of its,third drug ... is currently,in clinical trials and CF102, which is ... the EUALR annual congress of,rheumatology in-vitro and in ...
... of SLE,disease at 52 Weeks and demonstrated ... ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- ... of Phase 2,trial data demonstrating that LymphoStat-B(R) ... was well tolerated and improved quality of ...
Cached Medicine Technology:Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8